Trial Profile
Predictors of Treatment Response to Aflibercept and Aqueous Cytokine Levels in Patients With Persistent Diabetic Macular Edema Following Treatment With Ranibizumab: An Interventional Prospective Study
Status:
Not yet recruiting
Phase of Trial:
Phase IV
Latest Information Update: 04 Feb 2021
Price :
$35
*
At a glance
- Drugs Aflibercept (Primary)
- Indications Diabetic macular oedema
- Focus Pharmacodynamics
- 27 Jan 2016 New trial record